Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
7.11
+0.25 (3.64%)
Oct 27, 2025, 10:37 AM EDT - Market open
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $677.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $8.36M, down -76.27% year-over-year. In the year 2024, Relay Therapeutics had annual revenue of $10.01M, down -60.83%.
Revenue (ttm)
$8.36M
Revenue Growth
-76.27%
P/S Ratio
133.08
Revenue / Employee
$32,011
Employees
261
Market Cap
1.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RLAY News
- 2 days ago - Relay Therapeutics Is A Buy For Its Superb Safety Data - Seeking Alpha
- 6 weeks ago - Relay Therapeutics, Inc. (RLAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewsWire
- 2 months ago - Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 3 months ago - Relay Therapeutics: What's Next For H2 2025? - Seeking Alpha
- 3 months ago - Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 - GlobeNewsWire
- 4 months ago - Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - GlobeNewsWire
- 5 months ago - Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 - GlobeNewsWire